Cynata Therapeutics: Receives approval for acute graft-versus-host disease clinical trial

Cynata Therapeutics Receives approval for acute graft-versus-host disease clinical trial

  • Cynata Therapeutics (CYP) receives approval to launch a phase two clinical trial in acute graft-versus-host disease
  • The clinical stage biotech company was granted the green light to undertake the trial from Advarra, a central institutional research board (IRB) service provider in the US
  • IRB approval is considered an “essential step” in the process of opening clinical study sites and starting trials in humans in America
  • Cynata expects the trial will be conducted in around 60 patients at sites across the US, Europe, and Australia
  • CynataTherapeutics last traded at 31 cents at 2:47 pm AEDT
Rinsu Ann Easo
Rinsu Ann Easo
Diligent Technical Lead with 9 years of experience in software development. Successfully lead project management teams to build technological products. Exposed to software development life cycle including requirement analysis, program design, development and unit testing and application maintenance. Has worked on Java, PHP, PL/SQL, Oracle forms and Reports, Oracle, Bootstrap, structs, jQuery, Ajax, java script, CSS, Microsoft Excel, Microsoft Word, C++, and Microsoft Office.

You May Also Like

NYSE Parent Invests $600M in Polymarket, Strengthening Market Position

This significant investment signals confidence in the future of predictive markets.Highlights: NYSE's parent company allocates $600M to Polymarket.Investment...

Nexi Expands SEPA Direct Debit with Danish Banks, Enhancing Payments Integration

Nexi's collaboration with Danish banks aims to strengthen payment services across Europe.Highlights: Nexi partners with several Danish banks...

Lloyds Confirms App Glitch Exposed Data of Almost Half a Million Customers

The significant data breach prompts concerns over customer privacy.Highlights: Lloyds Banking Group admits to a data breach affecting...

Mastercard Restricts Sale of Nets Payments Unit Purchased for $3.2 Billion

Mastercard looks to divest its Nets payments segment as part of strategic realignment.Highlights: Mastercard is seeking to sell...